BridgeMD
New treatment option for Healthy Adult Subject
Official title A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects
ClinicalTrials.gov ID: NCT07594847
What this study is testing
What is HDM1002 200 mg?
HDM1002 200 mg is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for healthy adult subject.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45. Healthy volunteers may be eligible.
You may be able to join if
- The subject has voluntarily signed a written informed consent form.
- Male or female; age between 18 and 45 years (inclusive).
- Subject's weight ≥50 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m2, inclusive. BMI = weight (kg) / height2 (m2).
- Medical history inquiry, physical examination, laboratory test items, and other trial-related tests at screening are all normal or show mild...
- The subject is able to communicate well with the investigator and comply with the protocol requirements to complete the study.
You likely can't join if
- History of or current neurological/psychiatric, respiratory, cardiovascular, gastrointestinal, hematological and lymphatic, endocrine, or...
- people with a personal or family history of medullary thyroid cancer (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2);
- History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening;
- History of a cholecystitis episode within 3 months prior to screening;
- History of allergy to HDM1002, moxifloxacin hydrochloride tablets, other fluoroquinolones or quinolones, or any of the excipients; or history of food...
- Clinically significant major illness or undergone major surgery within 3 months prior to the trial;
See the full eligibility criteria
- The subject has voluntarily signed a written informed consent form.
- Male or female; age between 18 and 45 years (inclusive).
- Subject's weight ≥50 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m2, inclusive. BMI = weight (kg) / height2 (m2).
- Medical history inquiry, physical examination, laboratory test items, and other trial-related tests at screening are all normal or show mild abnormalities with no clinical significance, and the subject is judged to be...
- The subject is able to communicate well with the investigator and comply with the protocol requirements to complete the study.
- History of or current neurological/psychiatric, respiratory, cardiovascular, gastrointestinal, hematological and lymphatic, endocrine, or musculoskeletal system diseases, hepatic or renal insufficiency, or any other...
- people with a personal or family history of medullary thyroid cancer (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2);
- History of chronic pancreatitis or an episode of acute pancreatitis within 3 months prior to screening;
- History of a cholecystitis episode within 3 months prior to screening;
- History of allergy to HDM1002, moxifloxacin hydrochloride tablets, other fluoroquinolones or quinolones, or any of the excipients; or history of food allergy, or a specific allergy history (asthma, urticaria, eczema...
- Clinically significant major illness or undergone major surgery within 3 months prior to the trial;
- Blood donation within 3 months, or plans to donate blood during this study, or transfusion or blood loss ≥200 mL within 4 weeks prior to the trial;
- Has consumed a special diet, engaged in strenuous exercise, or had other factors that affect drug absorption, distribution, metabolism, and excretion within 48 hours prior to dosing;
- Pregnant or lactating, or has a positive blood pregnancy test result;
- The investigator believes that the subject has any other condition that makes them unsuitable for participation in this clinical trial.
The study team makes the final eligibility decision.
Where it's taking place
- Zibo, Shangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zibo, Shangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.